![Hoe eenvoudige semantiek onze AI-citaties met 642% verhoogde [Nieuwe resultaten]](https://www.pharmamarketeer.nl/wp-content/uploads/2026/01/719-370x300.jpg)
New Phase 3 data has been released on Johnson & Johnson’s selective sphingosine-1-phosphate receptor 1 (S1P1) modulator ponesimod, reporting that the drug performed favourably compared to Genzyme’s Aubagio...
New medical imaging device could help cut time and cost of procedures
Researchers have completed a successful clinical trial, managing to detect and image radioactive tracers used in PET and in SPECT scans at the same time, with the hope of enabling doctors to scan patients for...
Lilly’s Baqsimi nasal powder gains FDA approval after proving non-inferior to injection
Eli Lilly has been awarded approval from the FDA for its Baqsimi nasal powder in the treatment of severe hypoglycaemia, it has emerged, marking the authorisation of the first glucagon therapy in this indication in the...
AstraZeneca’s Lynparza scores limited NICE backing for new first-line maintenance use
With competitors racking up new indications and data wins, AstraZeneca’s Lynparza is looking to keep its lead in the PARP inhibitor field. England’s cost watchdog delivered a leg up Friday with a new recommendation—a...
2020 Content Marketing: What’s Clear and What Needs to Be in Focus
If hindsight is 20/20, then this article offers both hindsight and foresight. Over 25 CMWorld 2019 speakers put on their 2020 content marketing glasses to see where marketers are passing the vision test – and what’s...
Want to Scale Your Content Marketing? Get the Employees Involved
Every person has a story to tell. And if you are a smart content marketer, you know that every employee has a story that can sell your brand. If you want to scale your content marketing, you must look to the brand’s...
Acadia’s schizophrenia drug flops in Phase 3 trial
Acadia Pharmaceuticals has said its schizophrenia drug Nuplazid (primavanserin) has failed to beat placebo in a Phase 3 trial. Nuplazid did not improve symptoms as an adjunctive treatment in adult patients with...
Myovant has second phase 3 trial to back its uterine fibroids drug
Aims to take on AbbVie in new market
Vertex files cystic fibrosis triple therapy with FDA
A landmark for company – but pricing controversy awaits
FDA approves Pfizer’s biosimilar version of Genentech’s Rituxan
Pfizer has seen Ruxience, its biosimilar version of Genentech’s Rituxan (rituximab), approved by the FDA in the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukaemia, and granulomatosis with polyangiitis and...
Humira biosimilar from Samsung Bioepis and MSD wins marketing authorisation in the US
It’s another victory for MSD as the US drugmaker announced that its biosimilar version of AbbVie’s Humira – the world’s best-selling medicine – has received marketing authorisation from the FDA. The approval for the...
Canada wil samenwerken met Nederland omtrent geneesmiddelen
Canada en Nederland gaan mogelijk samenwerken bij het aanpakken van problemen rond dure geneesmiddelen. Minister Bruno Bruins voor Medische Zorg heeft hierover gesproken met zijn Canadese collega Simon Kennedy.
New EU-funded project helping to develop safer, more effective medicines
Chiral pharmaceuticals are widely used in clinical treatments and agriculture. They include non-steroid anti-inflammatory drugs, β-blockers for reducing blood pressure, and herbicides and pesticides.
Flyers als marketinginstrument
De gedachte dat flyers nutteloos zijn als marketinginstrument is niet nodig. Flyers zijn juist een heel goed marketinginstrument.
GSK sets out plan to double drug discovery success
Staff encouraged to take more risks in pursuit of blockbuster medicines
Online of offline marketing: welke strategie is effectiever?
Marketing is een van de belangrijkste aspecten van de moderne bedrijfsvoering.
[column] Vijf redenen om podcasts op te nemen in je marketingmix
Podcasting is niet nieuw, maar wel hot. Het biedt enorm veel kansen. Oók B2B en voor kleine merken. Eigenlijk kunnen we er niet langer omheen.
7 Easy Ways to Super Boost Your Newsletter Open Rate
Your newsletter isn’t beans. You can’t sprout the open rate overnight. However, if you lay the groundwork with targeted and well-researched strategies, your newsletter will grow uncannily fast just like bamboo shoots...
